Fludarabine and melphalan conditioning with tacrolimus as GVHD prophylaxis for allogeneic stem cell transplant recipients is an effective reduced-intensity combination regimen compared to the conventional regimen

International Journal of Clinical Oncology

Volumn 14, Issue 3, 2009, Pages 197-201

  Imataki, Osamu ^a   Ohnishi, Hiroaki ^a   Ohbayashi, Yumiko ^a   Kitanaka, Akira ^a   Kubota, Yoshitsugu ^a   Ishida, Toshihiko ^a   Tanaka, Terukazu ^b  

^a KAGAWA UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

Allogeneic stem cell transplantation (allo SCT); Conventional stem cell transplantation (CST); Fludarabine and melphalan; Reduced intensity stem cell transplantation (RIST)

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; MELPHALAN; METHOTREXATE; TACROLIMUS; DRUG DERIVATIVE; VIDARABINE;

ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEMALE; GRAFT VERSUS HOST REACTION; HLA SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RADIATION DOSE; REDUCED INTENSITY CONDITIONING; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; COMPARATIVE STUDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TEST; IMMUNOSUPPRESSIVE TREATMENT; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; TACROLIMUS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 70349567600     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-008-0826-7     Document Type: Article

References (14)

1. E.D. Thomas 1983 Karnofsky Memorial Lecture. Marrow transplantation for malignant diseases J Clin Oncol 1 517 531 6366143 1:STN:280:DyaL2c7jslynsw%3D%3D
2. P. Satwani L. Harrison E. Morris, et al. 2005 Reduced-intensity allogeneic stem cell transplantation in adults and children with malignant and nonmalignant diseases: end of the beginning and future challenges Biol Blood Marrow Transplant 11 403 422 15931629 10.1016/j.bbmt.2005.04.002 (Pubitemid 40753793)
3. A.A. Kassim W. Chinratanalab J.L. Ferrara S. Mineishi 2005 Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: "what is the best recipe?" Bone Marrow Transplant 36 565 574 15995714 10.1038/sj.bmt.1705075 1:STN:280:DC%2BD2MvptFGnsw%3D%3D (Pubitemid 43115011)
4. R. Chakraverty K. Peggs R. Chopra, et al. 2002 Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen Blood 99 1071 1078 11807015 10.1182/blood.V99.3.1071 1:CAS:528:DC%2BD38XhtValt7k%3D (Pubitemid 34525573)
5. S. Giralt E. Estey M. Albitar, et al. 1997 Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy Blood 89 4531 4536 9192777 1:CAS:528:DyaK2sXjvFCkt7g%3D
6. S. Giralt P.F. Thall I. Khouri, et al. 2001 Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation Blood 97 631 637 11157478 10.1182/blood.V97.3.631 1:CAS:528:DC%2BD3MXhtVSjsL0%3D (Pubitemid 32113394)
7. M. de Lima A. Anagnostopoulos M. Munsell, et al. 2004 Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation Blood 104 865 872 15090449 10.1182/blood-2003-11-3750 (Pubitemid 38970586)
8. G.R. Hill J.L. Ferrara 2000 The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation Blood 95 2754 2759 10779417 1:CAS:528:DC%2BD3cXivVarurw%3D
9. M. Mielcarek P.J. Martin W. Leisenring, et al. 2003 Graft-versushost disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation Blood 102 756 762 12663454 10.1182/blood-2002-08-2628 1:CAS:528:DC%2BD3sXlslGiurg%3D (Pubitemid 36842003)
10. D.R. Couriel R.M. Saliba S. Giralt, et al. 2004 Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation Biol Blood Marrow Transplant 10 178 185 14993883 10.1016/j.bbmt.2003.10.006 (Pubitemid 38262880)
11. B.M. Sandmaier S. Mackinnon R.W. Childs 2007 Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives Biol Blood Marrow Transplant 13 1Suppl1 87 97 17222778 10.1016/j.bbmt.2006.10.015 (Pubitemid 46044111)
12. S. Tauro C. Craddock K. Peggs, et al. 2005 Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia J Clin Oncol 23 9387 9393 16314618 10.1200/JCO.2005.02.0057 1:CAS:528:DC%2BD28Xnt1ymtg%3D%3D (Pubitemid 46260198)
13. Y. Inamoto T. Oba K. Miyamura, et al. 2006 Stable engraftment after a conditioning regimen with fludarabine and melphalan for bone marrow transplantation from an unrelated donor Int J Hematol 83 356 362 16757439 10.1532/IJH97.05168 (Pubitemid 43807583)
14. M. Yanada N. Emi T. Naoe, et al. 2004 Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan Bone Marrow Transplant 34 331 337 15220958 10.1038/sj.bmt.1704596 1:CAS:528: DC%2BD2cXmtFGjt70%3D (Pubitemid 39172440)